Clinical development of nintedanib for advanced non-small-cell lung cancer
Masayuki Takeda,1 Isamu Okamoto,2 Kazuhiko Nakagawa1 1Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, 2Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Abstract: Angiogenesis is an essential process in t...
Guardado en:
Autores principales: | Takeda M, Okamoto I, Nakagawa K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/808145f91b5440898b5eefb2a5159d90 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer
por: Hiroyuki Sayama, et al.
Publicado: (2021) -
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
por: Joy C. Hsu, et al.
Publicado: (2021) -
Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer
por: Ying Liu, et al.
Publicado: (2022) -
Immunocytokines: a review of molecules in clinical development for cancer therapy
por: List T, et al.
Publicado: (2013) -
“Highly Exposed Chinese Herbal Medicine” Combined With Apatinib as Maintenance Treatment Following First-Line or Second-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Single-Arm, Prospective Study
por: Mingqi Wang, et al.
Publicado: (2021)